High-Dose Calcitriol, Zoledronate, and Dexamethasone for the Treatment of Progressive Prostate Carcinoma

Cancer

Volumn 100, Issue 9, 2004, Pages 1868-1875

  Morris, Michael J ^a,b   Smaletz, Oren ^c   Solit, David ^a,b   Kelly, W Kevin ^a,b   Slovin, Susan ^a,b   Flombaum, Carlos ^a,b   Curley, Tracy ^a   Delacruz, Anthony ^a   Schwartz, Lawrence ^a,b   Fleisher, Martin ^a   Zhu, Andrew ^d   Diani, Meghan ^a   Fallon, Mary ^a   Scher, Howard I ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Bisphosphonates; Prostate carcinoma; Steroid hormones; Vitamin D

Indexed keywords

CALCITRIOL; CALCIUM; CREATININE; DEXAMETHASONE; ROCATROL; ZOLEDRONIC ACID;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; BLOOD TOXICITY; BONE PAIN; BONE TURNOVER; CALCIUM BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG MEGADOSE; DRUG TOLERABILITY; DYSURIA; FATIGUE; GASTROINTESTINAL TOXICITY; HUMAN; HYDRONEPHROSIS; HYPERCALCEMIA; HYPERCALCIURIA; HYPERGLYCEMIA; HYPOCALCEMIA; HYPOPHOSPHATEMIA; LABORATORY TEST; LUNG TOXICITY; MALE; MAXIMUM TOLERATED DOSE; MEDICAL DOCUMENTATION; METABOLIC DISORDER; MYALGIA; NEPHROLITHIASIS; NEPHROTOXICITY; NEUROPATHY; PNEUMONIA; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTHROMBIN TIME; SIDE EFFECT; THROMBOSIS; TOXICITY; TREATMENT OUTCOME; UROGENITAL TRACT DISEASE;

AGED; AGED, 80 AND OVER; CALCITRIOL; CARCINOMA; COHORT STUDIES; DEXAMETHASONE; DIPHOSPHONATES; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FOLLOW-UP STUDIES; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; PULSE THERAPY, DRUG; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 11144354458     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20185     Document Type: Article

References (29)

1. Simboli-Campbell M, Narvaez CJ, Tenniswood M, Welsh J. 1,25-Dihydroxyvitamin D3 induces morphological and biochemical markers of apoptosis in MCF-7 breast cancer cells. J Steroid Biochem Mol Biol. 1996;58:367-376.
2. Welsh J, Simboli-Campbell M, Narvaez CJ, Tenniswood M. Role of apoptosis in the growth inhibitory effects of vitamin D in MCF-7 cells. Adv Exp Med Biol. 1995;375:45-52.
3. Hershberger PA, Modzelewski RA, Shurin ZR, Rueger RM, Trump DL, Johnson CS. 1,25-Dihydroxycholecalciferol (1,25-D3) inhibits the growth of squamous cell carcinoma and down-modulates p21(Waf1/Cip1) in vitro and in vivo. Cancer Res. 1999;59:2644-2649.
4. Studzinski GP, Bhandal AK, Brelvi ZS. Cell cycle sensitivity of HL-60 cells to the differentiation-inducing effects of 1-alpha,25-dihydroxyvitamin D3. Cancer Res. 1985;45:3898-3905.
5. Evans RM. The steroid and thyroid hormone receptor superfamily. Science. 1988;240:889-895.
6. Schwartz G, Hulka B. Is vitamin D deficiency a risk factor for prostate cancer? Anticancer Res. 1990;10:1307-1311.
7. Weigel NL. Steroid hormone receptors and their regulation by phosphorylation. Biochem J. 1996;319:657-667.
8. Slater SJ, Kelly MB, Taddeo FJ, et al. Direct activation of protein kinase C by 1a,25-dihydroxyvitamin D3. J Biol Chem. 1995;270:6639-6643.
9. Gniadecki R. Activation of Raf-mitogen-activated protein kinase signaling pathway by 1,25-dihydroxyvitamin D3 in normal human keratinocytes. J Invest Dermatol. 1996;106:1212-1217.
10. Johnson CS, Hershberger PA, Bernardi RJ, McGuire TF, Trump DL. Vitamin D receptor: a potential target for intervention. Urology. 2002;60(3 Suppl 1):123-130; discussion, 130-131.
11. Miller GJ, Stapleton GE, Ferrara JA, et al. The human prostatic carcinoma cell line LNCaP expresses biologically active, specific receptors for 1a,25-dihydroxyvitamin D3. Cancer Res. 1992;52:515-520.
12. Skowronski RJ, Peehl D, Feldman D. Vitamin D and prostate cancer: 1,25-dihydroxyvitamin D3 receptors and actions in prostate cancer cell lines. Endocrinology. 1993;132:1952-1960.
13. Peehl DM, Skowronski RJ, Leung GK, Wong ST, Stamey TA, Feldman D. Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells. Cancer Res. 1994;54:805-810.
14. Miller GJ, Stapleton GE, Hedlund TE, Moffatt KA. Vitamin D receptor expression, 24-hydroxylase activity, and inhibition of growth by 1a,25-dihydroxyvitamin D3 in seven human prostatic carcinoma cell lines. Clin Cancer Res. 1995;1:997-1003.
15. Oades GM, Dredge K, Kirby RS, Colston KW. Vitamin D receptor-dependent antitumour effects of 1,25-dihydroxyvitamin D3 and two synthetic analogues in three in vivo models of prostate cancer. BJU Int. 2002;90:607-616.
16. Getzenberg RH, Light BW, Lapco PE, et al. Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system. Urology. 1997;50:999-1006.
17. Osborne JL, Schwartz GG, Smith DC, Bahnson RR, Day R, Trump DL. A Phase II trial of oral 1,25-dihydroxyvitamin D (calcitriol) in hormone refractory prostate cancer. Urol Oncol. 1995;1:195-198.
18. Gross C, Stamey T, Hancock S, Feldman D. Treatment of early recurrent prostate cancer with 1,25-dihydroxyvitamin D3 (calcitriol). J Urol. 1998;159:2035-2040.
19. Trump D, Serafine S, Brufsky A, et al. High dose calcitriol (1,25(OH)2 vitamin D3) + dexamethasone in androgen independent prostate cancer (AIPC) [abstract]. Proc Am Soc Clin Oncol. 2000;19:337a.
20. Beer TM, Munar M, Henner WD. A Phase I trial of pulse calcitriol in patients with refractory malignancies: pulse dosing permits substantial dose escalation. Cancer. 2001;91:2431-2439.
21. Yu WD, McElwain MC, Modzelewski RA, et al. Enhancement of 1,25-dihydroxyvitamin D3-mediated antitumor activity with dexamethasone. J Natl Cancer Inst. 1998;90:134-141.
22. Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002;94:1458-1468.
23. Smith DC, Johnson CS, Freeman CC, Muindi J, Wilson JW, Trump DL. A Phase I trial of calcitriol (1,25-dihydroxychole-calciferol) in patients with advanced malignancy. Clin Cancer Res. 1999;5:1339-1345.
24. Muindi JR, Peng Y, Potter DM, et al. Pharmacokinetics of high-dose oral calcitriol: results from a Phase 1 trial of calcitriol and paclitaxel. Clin Pharmacol Ther. 2002;72:648-659.
25. Novartis Pharma AG. Zometa® [package insert]. Basel: Novartis, 2002.
26. Skowronski RJ, Peehl DM, Feldman D. Actions of vitamin D3, analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3. Endocrinology. 1995;136:20-26.
27. Beer TM, Eilers KM, Garzotto M, Egorin MJ, Lowe BA, Henner WD. Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. J Clin Oncol. 2003;21:123-128.
28. Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol. 1996;14:1756-1764.
29. Kantoff PW, Halabi S, Conaway M, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the Cancer and Leukemia Group B 9182 study. J Clin Oncol. 1999;18:2506-2513.